Tositumomab/Iodine-131 Tositumomab Regimen for Non-Hodgkin Lymphoma to Be Discontinued
GlaxoSmithKline announced today that it will discontinue the manufacture and sale of the tositumomab/iodine-131 tositumomab (Bexxar) therapeutic regimen on February 20, 2014.
Tositumomab/iodine-131 tositumomab is currently approved in the United States and Canada for the treatment of patients with CD20-positive relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin lymphoma (NHL) who have progressed during or after rituximab (Rituxan) therapy, including patients with rituximab-refractory NHL. The regimen is only indicated for a single course of treatment, and the safety and efficacy of additional courses of treatment have not been established.
According to the company, the use of tositumomab/iodine-131 tositumomab has been extremely limited and is projected to continue to decline. Additionally, there are other treatment options available for patients with relapsed NHL.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
